US Bancorp’s Avita Medical RCEL Stock Holding History

US Bancorp’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,700	Closed	-$8.99K	–	4232
2025 Q2	$8.99K	Hold	1,700	–	–	﹤0.01%	3465
2025 Q1	$13.8K	Buy	+1,700	New	+$15.9K	﹤0.01%	3328

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $4.41B AUM 90.53% 1-Year Est. Return

US Bancorp's RCEL Position: Q3 2025 in Review

US Bancorp sold out of Avita Medical (RCEL) in Q3 2025, closing a stake of 1,700 shares — an estimated $8.99K sold.

US Bancorp first reported a position in RCEL in Q1 2025 and held it in 2 quarters. The position peaked at $13.8K in Q1 2025. 76 funds tracked by Wall St. Rank hold RCEL as of Q3 2025.

US Bancorp reported no remaining Avita Medical position as of Q3 2025 after selling out during the quarter.
US Bancorp sold 1,700 Avita Medical shares in Q3 2025, an estimated $8.99K.
US Bancorp first reported a position in Avita Medical in Q1 2025 and held it in 2 quarters.
US Bancorp's Avita Medical position peaked at $13.8K in Q1 2025.
76 funds tracked by Wall St. Rank held Avita Medical as of Q3 2025.

Based on US Bancorp's 13F filing for Q3 2025, filed 12 Nov 2025.